RxDoctor Payments DataLook up a doctor →

T Rao, MD

Neurology · Charlotte, NCNPI 1023070745

Payments from drug & device makers

$4,024,666in general payments, 2019–2025

Across 420 payments — averaging $9582.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$2M
  • UCB SA$558K
  • F. Hoffmann-la Roche AG$505K
  • Sanofi US Services Inc.$414K
  • Janssen Research & Development, LLC$253K
  • Roche Products Limited$132K
  • plus $196K from 9 others
$3,120in research payments, 2019–2025

Across 1 payment — averaging $3120.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • UCB, Inc.$3K

What the payments were for

  • Education$6100%

General payments by program year

19
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,024,666 in reported general payments places this provider in the 95th percentile of 566 neurology providers in North Carolina.

See all neurology providers in North Carolina

Medicare billing

Part B allowed, 2024
$425,108
Medicare patients
194
Services billed
1,097

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5077$2,664,783
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5081$1,775,750
GammakedImmune Globul G/Gly/Iga Avg 4638$1,256,168
PanzygaImmun Glob G(Igg)-Ifas/Glycine76$1,112,283
OctagamImmun Globg(Igg)/Malt/Iga Ov5023$608,117
FirdapseAmifampridine Phosphate14$430,295
Kesimpta PenOfatumumab25$312,530
RebifInterferon Beta-1a/Albumin12$126,143
Avonex (4 Pack)Interferon Beta-1a12$96,437
Teriflunomide19$14,263
BotoxOnabotulinumtoxina14$10,854
Rivastigmine44$10,249
Ajovy SyringeFremanezumab-Vfrm11$8,729
Droxidopa21$4,388
AmantadineAmantadine Hcl84$3,494

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BiogenAvonex (4 Pack)$86$96,43712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 566 neurology providers in North Carolina.

Other neurology in Charlotte

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →